(1<i>S</i>)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-<scp>d</scp>-glucitol (TS-071) is a Potent, Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for Type 2 Diabetes Treatment
作者:Hiroyuki Kakinuma、Takahiro Oi、Yuko Hashimoto-Tsuchiya、Masayuki Arai、Yasunori Kawakita、Yoshiki Fukasawa、Izumi Iida、Naoko Hagima、Hiroyuki Takeuchi、Yukihiro Chino、Jun Asami、Lisa Okumura-Kitajima、Fusayo Io、Daisuke Yamamoto、Noriyuki Miyata、Teisuke Takahashi、Saeko Uchida、Koji Yamamoto
DOI:10.1021/jm901893x
日期:2010.4.22
Derivatives of a novel scaffold, C-phenyl 1-thio-d-glucitol, were prepared and evaluated for sodium-dependent glucose cotransporter (SGLT) 2 and SGLT1 inhibition activities. Optimization of substituents on the aromatic rings afforded five compounds with potent and selective SGLT2 inhibition activities. The compounds were evaluated for in vitro human metabolic stability, human serum protein binding
一种新颖的支架的衍生物,c ^ -苯基-1-硫代d -glucitol,制备并评价为钠依赖性葡萄糖协同转运蛋白(SGLT)2个SGLT1抑制活性。优化芳环上的取代基可得到五种具有有效和选择性SGLT2抑制活性的化合物。评价了这些化合物的体外人类代谢稳定性,人类血清蛋白结合(SPB)和Caco-2渗透性。它们中,(1个小号)-1,5-脱水-1- [5-(4-乙氧基苄基)-2-甲氧基-4-甲基苯基] -1-硫代d -glucitol(3P)显示出强效的SGLT2抑制活性( IC 50 = 2.26 nM),选择性是SGLT1的1650倍。复合3p对冷冻保存的人肝清除率,较低的SPB和适度的Caco-2通透性显示出良好的代谢稳定性。由于3p应该具有可接受的人体药代动力学(PK)特性,因此它可能是治疗2型糖尿病的临床候选药物。我们观察到化合物3p在动物中表现出降血糖作用,出色的尿葡萄糖排泄特性和有